[ORGANIZATION]
Merck (MSD)
Featured in 1 tracked story · first seen
Situations
Samsung Bioepis SB27 Keytruda biosimilar development
3 clusters · 4 sources · last updated
Latest: Samsung Bioepis confirms clinical equivalence for Keytruda biosimilar SB27
Samsung Bioepis has advanced the development of SB27, a biosimilar candidate for the immunotherapy drug Keytruda. At the 2026 ESMO annual meeting, the company reported Phase 1 clinical trial results involving 163 non-sma